Form 4: Karen Peacock Acquires IDEXX Laboratories Stock Options

Director Karen Peacock acquired stock options and deferred stock units in IDEXX LABORATORIES INC.

Summary

• Karen Peacock, a Director at IDEXX LABORATORIES INC, acquired new equity awards.
• Specifically, she was granted a non-qualified stock option to buy 525 shares of common stock at an exercise price of $533.92, with an expiration date of May 11, 2036.
• Additionally, she received 234 deferred stock units, each representing a contingent right to one share of common stock.
• Both the stock options and deferred stock units vest in one installment on the one-year anniversary of the grant date or the 2027 annual meeting of shareholders, whichever comes first.
• These transactions were reported on May 12, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents standard equity compensation for a director, indicating continued engagement and alignment with the company's long-term prospects.

Positives

• Director Karen Peacock has been granted stock options and deferred stock units, indicating continued alignment with shareholder interests.
• The grant of equity awards suggests management's confidence in the company's future performance.
• The vesting schedule ties equity realization to future company performance and director tenure.

Risks

• The value of the stock options and deferred stock units is subject to market fluctuations and the future performance of IDEXX LABORATORIES INC.
• The vesting is contingent on remaining a director until the vesting date or the 2027 annual meeting, implying a risk of forfeiture if the director resigns or is removed before then.

Future Outlook

The grant of stock options and deferred stock units with vesting tied to future dates suggests a positive outlook for the company's performance, as these awards are intended to incentivize long-term value creation.

Industry Context

StockSavvy.ai notes that the issuance of stock options and deferred stock units to directors is a common practice in the biotechnology and animal health industry, aligning executive and director compensation with shareholder value and long-term company growth.

Stakeholder Impact

• Shareholders: The grant of equity awards to directors aligns their interests with shareholders, potentially driving long-term value creation.
• Employees: While not directly impacted, such grants can reflect a healthy company culture and commitment to performance-based incentives.
• Management: Reinforces the compensation structure for key leadership.

Next Steps

• Vesting of stock options and deferred stock units on the one-year anniversary of the grant date or the 2027 annual meeting of shareholders, whichever is earlier.
• Potential exercise of stock options by Karen Peacock after vesting.
• Payment of deferred stock units as common stock upon resignation from the Board of Directors.

Key Dates

Keywords

IDEXX LABORATORIES INC, Karen Peacock, Form 4, Stock Options, Deferred Stock Units, Insider Trading, Equity Awards, SEC Filing